Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma

Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Breakthrough brings potential glioblastoma drug into focus

A new class of small molecule drugs, now in phase 1 clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and…

Powerful Bragg reflector with ultrahigh refractive index metamaterial

We all look in the mirror at least once a day to see our reflection. Mirrors are used not only in daily life but also in cutting-edge technologies such as…

Casting shadows on solar cells connected in series

In shaded conditions, photovoltaics linked end-to-end experience more power loss than cells running in parallel. Large obstacles, like clouds and buildings, can block sunlight from reaching solar cells, but smaller…

Partners & Sponsors